FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384807165> ?p ?o ?g. }

• W4384807165 endingPage "1025" @default.
• W4384807165 startingPage "1025" @default.
• W4384807165 abstract "A series of novel enantiopure isoxazolidine derivatives were synthesized and evaluated for their anticancer activities against three human cancer cell lines such as human breast carcinoma (MCF-7), human lung adenocarcinoma (A-549), and human ovarian carcinoma (SKOV3) by employing MTT assay. The synthesized compounds were characterized by NMR and elemental analysis. Results revealed that all the synthesized compounds displayed significant inhibition towards the tested cell lines. Among them, 2g and 2f, which differ only by the presence of an ester group at the C-3 position and small EDG (methyl) at the C-5 position of the phenyl ring (2g), were the most active derivatives in attenuating the growth of the three cells in a dose-dependent manner. The IC50 for 2g were 17.7 ± 1 µM (MCF-7), 12.1 ± 1.1 µM (A-549), and 13.9 ± 0.7 µM (SKOV3), and for 2f were 9.7 ± 1.3µM (MCF-7), 9.7 ± 0.7µM (A-549), and 6.5 ± 0.9µM (SKOV3), respectively, which were comparable to the standard drug, doxorubicin. The enzymatic inhibition of 2f and 2g against EGFR afforded good inhibitory activity with IC50 of 0.298 ± 0.007 μM and 0.484 ± 0.01 µM, respectively, close to the positive control, Afatinib. Compound 2f arrested the cell cycle in the S phase in MCF-7 and SKOV3 cells, and in the G2/M phase in the A549 cell; however, 2g induced G0/G1 phase cell cycle arrest, and inhibited the progression of the three cancer cells, together with significant apoptotic effects. The docking study of compounds 2f and 2g into EGFR ATP-active site revealed that it fits nicely with good binding affinity. The pharmacokinetic and drug-likeness scores revealed notable lead-like properties. At 100 ns, the dynamic simulation investigation revealed high conformational stability in the EGFR binding cavity." @default.
• W4384807165 created "2023-07-20" @default.
• W4384807165 creator A5005764434 @default.
• W4384807165 creator A5009503447 @default.
• W4384807165 creator A5038617233 @default.
• W4384807165 creator A5039589699 @default.
• W4384807165 creator A5057583383 @default.
• W4384807165 creator A5062565762 @default.
• W4384807165 creator A5073711317 @default.
• W4384807165 creator A5077366181 @default.
• W4384807165 creator A5092498938 @default.
• W4384807165 date "2023-07-19" @default.
• W4384807165 modified "2023-09-27" @default.
• W4384807165 title "In Vitro and In Silico Evaluation of Antiproliferative Activity of New Isoxazolidine Derivatives Targeting EGFR: Design, Synthesis, Cell Cycle Analysis, and Apoptotic Inducers" @default.
• W4384807165 cites W1968059388 @default.
• W4384807165 cites W1977223721 @default.
• W4384807165 cites W2008129506 @default.
• W4384807165 cites W2016710415 @default.
• W4384807165 cites W2023913654 @default.
• W4384807165 cites W2028441801 @default.
• W4384807165 cites W2102189829 @default.
• W4384807165 cites W2129872991 @default.
• W4384807165 cites W2133051701 @default.
• W4384807165 cites W2593436234 @default.
• W4384807165 cites W2607491114 @default.
• W4384807165 cites W2615601352 @default.
• W4384807165 cites W2887448750 @default.
• W4384807165 cites W2949396247 @default.
• W4384807165 cites W2951577272 @default.
• W4384807165 cites W3020893404 @default.
• W4384807165 cites W3024505225 @default.
• W4384807165 cites W3024674456 @default.
• W4384807165 cites W3042897754 @default.
• W4384807165 cites W3081044980 @default.
• W4384807165 cites W3102083808 @default.
• W4384807165 cites W3104518517 @default.
• W4384807165 cites W3125034325 @default.
• W4384807165 cites W3134689785 @default.
• W4384807165 cites W3157900784 @default.
• W4384807165 cites W3173613138 @default.
• W4384807165 cites W3185869221 @default.
• W4384807165 cites W3186011493 @default.
• W4384807165 cites W3197730160 @default.
• W4384807165 cites W3204221006 @default.
• W4384807165 cites W4205945166 @default.
• W4384807165 cites W4214604701 @default.
• W4384807165 cites W4224251179 @default.
• W4384807165 cites W4225654115 @default.
• W4384807165 cites W4225717327 @default.
• W4384807165 cites W4281959671 @default.
• W4384807165 cites W4283068664 @default.
• W4384807165 cites W4283385195 @default.
• W4384807165 cites W4283776537 @default.
• W4384807165 cites W4286751549 @default.
• W4384807165 cites W4292756005 @default.
• W4384807165 cites W4293375484 @default.
• W4384807165 cites W4293691936 @default.
• W4384807165 cites W4293827105 @default.
• W4384807165 cites W4296638034 @default.
• W4384807165 cites W4308178020 @default.
• W4384807165 cites W4309705284 @default.
• W4384807165 cites W4312125591 @default.
• W4384807165 cites W4323043116 @default.
• W4384807165 cites W4375949851 @default.
• W4384807165 cites W4379230196 @default.
• W4384807165 cites W4380356794 @default.
• W4384807165 cites W4380989357 @default.
• W4384807165 cites W4381804718 @default.
• W4384807165 cites W4383228184 @default.
• W4384807165 doi "https://doi.org/10.3390/ph16071025" @default.
• W4384807165 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37513936" @default.
• W4384807165 hasPublicationYear "2023" @default.
• W4384807165 type Work @default.
• W4384807165 citedByCount "0" @default.
• W4384807165 crossrefType "journal-article" @default.
• W4384807165 hasAuthorship W4384807165A5005764434 @default.
• W4384807165 hasAuthorship W4384807165A5009503447 @default.
• W4384807165 hasAuthorship W4384807165A5038617233 @default.
• W4384807165 hasAuthorship W4384807165A5039589699 @default.
• W4384807165 hasAuthorship W4384807165A5057583383 @default.
• W4384807165 hasAuthorship W4384807165A5062565762 @default.
• W4384807165 hasAuthorship W4384807165A5073711317 @default.
• W4384807165 hasAuthorship W4384807165A5077366181 @default.
• W4384807165 hasAuthorship W4384807165A5092498938 @default.
• W4384807165 hasBestOaLocation W43848071651 @default.
• W4384807165 hasConcept C104317684 @default.
• W4384807165 hasConcept C105696609 @default.
• W4384807165 hasConcept C121608353 @default.
• W4384807165 hasConcept C185592680 @default.
• W4384807165 hasConcept C190283241 @default.
• W4384807165 hasConcept C202751555 @default.
• W4384807165 hasConcept C2775905019 @default.
• W4384807165 hasConcept C2776694085 @default.
• W4384807165 hasConcept C2777292972 @default.
• W4384807165 hasConcept C2777366897 @default.
• W4384807165 hasConcept C2777752497 @default.
• W4384807165 hasConcept C2780783641 @default.
• W4384807165 hasConcept C2781303535 @default.

• next